Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Chonnam Med J ; 51(3): 139-41, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26730366

ABSTRACT

We report the case of a 20-year-old man with a 2-month history of anal pain and bloody rectal discharge. He was referred to our clinic of gastroenterology for suspected inflammatory bowel disease (IBD). The colonoscopy showed mucosal nodularities on the rectum and an anal tag. Because the colonoscopic findings were not consistent with the typical manifestations of IBD, we took an additional sexual history and performed studies for infectious proctitis, including serologic tests for Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum. He had homosexual experience, and the serologic tests and PCR of a rectal swab were positive for C. trachomatis infection. Finally he was diagnosed as having chlamydial proctitis and was treated with intramuscular ceftriaxone 250 mg in a single dose and doxycycline 100 mg orally twice daily for 7 days. After 2 months, he had no lower abdominal symptoms and his endoscopic findings were improved.

2.
Korean J Gastroenterol ; 61(6): 319-26, 2013 Jun.
Article in Korean | MEDLINE | ID: mdl-23877212

ABSTRACT

BACKGROUND/AIMS: Incidentally detected focal 18F-fluorodeoxyglucose (FDG) uptake was compared with colonoscopy. We investigated the characteristics of colon adenomas which were revealed on PET/CT. Then we identified whether additional colonoscopy was necessary in patients with lesions which were revealed on PET/CT but had no matched lesions on colonoscopy. METHODS: We retrospectively reviewed 95 patients who underwent colonoscopy within a 6 month interval after they had focal FDG uptake from January 2010 to May 2012 at National Police Hospital in Korea. Also, we analyzed 30 patients who underwent additional colonoscopy within 2 years after they had no matched lesions on primary colonoscopy. RESULTS: PET/CT depicted 54.6% (41/75) of adenomas and adenocarcinomas. The PET visibility of colon adenoma was significantly associated with degree of dysplasia (p=0.027), histologic type (p=0.040), and the size (p=0.038). The positivity rate was increased with higher degree of dysplasia (low-grade dysplasia, 47%; high-grade dysplasia, 78%; adenocarcinoma, 100%) and villous patterns of histologic type (tubular, 46.8%; tubulovillous, 87.5%; villous, 100%). Patients with adenomas larger than 10 mm (87.5%) had higher detection rate compared to those with adenomas smaller than 10 mm (49.0%). Among the 30 patients who underwent additional colonoscopy, only one patient had a 6 mm sized tubular adenoma (low-grade dysplasia). CONCLUSIONS: Incidental focal colonic uptake may indicate advanced adenoma or adenocarcinoma. Thus, it justifies performing colonoscopy for identifying the presence of colon neoplasms. However, in case of unmatched lesions between PET/CT and colonoscopy, there was little evidence that additional colonoscopy would yield benefits.


Subject(s)
Colonic Neoplasms/diagnostic imaging , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/pathology , Adenoma/diagnostic imaging , Adenoma/pathology , Adult , Aged , Colonic Neoplasms/pathology , Colonic Polyps/pathology , Colonoscopy , Female , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Multimodal Imaging , Positron-Emission Tomography , Radiopharmaceuticals , Retrospective Studies , Tomography, X-Ray Computed
3.
Nucl Med Mol Imaging ; 46(1): 69-72, 2012 Mar.
Article in English | MEDLINE | ID: mdl-24900035

ABSTRACT

Due to the low yield of AFB smear and culture in extrapulmonary tuberculosis, therapeutic responses of patients with extrapulmonary tuberculosis are usually monitored clinically and/or radiographically. Such monitoring techniques, however, are not enough to provide effective diagnosis if a remnant lesion exists after treatment. Tuberculosis presents hypermetabolic activity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) scanning. Reported herein is a case of extrapulmonary tuberculosis where the therapeutic response was assessed via serial F-18 FDG PET/CT scanning, which was useful for detecting the extent of extrapulmonary tuberculosis and for estimating the patient's therapeutic response.

4.
J Korean Med Sci ; 25(12): 1802-4, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21165298

ABSTRACT

This report describes clinical and parasitological findings of an 82-yr-old female patient who lived in a local rural village and suffered from severe chronic anemia for several years. She was transferred to the National Police Hospital in Seoul for management of severe dyspnea and dizziness. At admission, she showed symptoms or signs of severe anemia. Gastroduodenoscopy observed hyperemic mucosa of the duodenum and discovered numerous moving roundworms on the mucosa. Endoscopy isolated seven of them, which were identified as Necator americanus by characteristic morphology of cutting plates in the buccal cavity. The patient was treated with albendazole and supportive measures for anemia, and her physical condition much improved. This case suggests the possibility that hookworm N. americanus is still transmitted in a remote local mountainous area in Korea.


Subject(s)
Anemia/diagnosis , Necator americanus , Necatoriasis/diagnosis , Aged, 80 and over , Albendazole/therapeutic use , Anemia/parasitology , Animals , Anthelmintics/therapeutic use , Duodenoscopy , Female , Gastroscopy , Humans , Necator americanus/isolation & purification , Necatoriasis/drug therapy , Republic of Korea
5.
J Gastroenterol ; 41(3): 240-9, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16699858

ABSTRACT

BACKGROUND: The management of patients with lamivudine-resistant mutants remains challenging, and no clear evidence has been presented concerning the discontinuation of lamivudine. METHODS: Seventy-four patients with lamivudine-resistant mutants were prospectively enrolled and randomized; 37 patients continued (group A) and 37 patients discontinued lamivudine therapy (group B). The median follow-up was 20 months. RESULTS: Serum albumin levels were reduced and prothrombin time was prolonged in both groups versus baseline (P = 0.015 and 0.045, respectively). Four patients in group A (10.8%) and six in group B (16.2%) experienced hepatitis flare, but the difference was not significant (P > 0.05). Multivariate analyses identified a younger age as a risk factor for hepatitis flare (P = 0.021). Seven (18.9%) decompensations occurred in group A and five (13.5%) in group B, which was not a significant difference (P > 0.05). Multivariate analyses revealed higher alanine aminotransferase and a lower platelet count as risk factors for hepatic decompensation (P = 0.001 and 0.001, respectively). The patients whose platelet count was <65 000/microl experienced hepatic decompensations more frequently (50%) than those with platelet counts >65 000/microl (13.2%) during follow-up (P = 0.05). CONCLUSIONS: The clinical course of group B was not significantly different from that of group A. Therefore, the discontinuation of lamivudine may be a feasible option when other antiviral agents active against lamivudine-resistant mutants are unavailable.


Subject(s)
Drug Resistance, Viral/drug effects , Lamivudine/therapeutic use , Liver Failure/epidemiology , Liver Failure/physiopathology , Mutation/drug effects , Reverse Transcriptase Inhibitors/therapeutic use , Adolescent , Adult , Aged , Alanine Transaminase/blood , Alanine Transaminase/drug effects , Bilirubin/blood , Biomarkers/blood , DNA, Viral/blood , DNA, Viral/drug effects , Disease Progression , Female , Follow-Up Studies , Hepatitis B e Antigens/blood , Hepatitis B e Antigens/drug effects , Hepatitis B virus/drug effects , Hepatitis B virus/metabolism , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/epidemiology , Hepatitis B, Chronic/virology , Humans , Korea/epidemiology , Lamivudine/adverse effects , Liver Failure/blood , Male , Middle Aged , Multivariate Analysis , Platelet Count , Predictive Value of Tests , Prospective Studies , Prothrombin Time , Reverse Transcriptase Inhibitors/adverse effects , Risk Factors , Serum Albumin/drug effects , Serum Albumin/metabolism
6.
Hepatogastroenterology ; 51(59): 1428-33, 2004.
Article in English | MEDLINE | ID: mdl-15362769

ABSTRACT

BACKGROUND/AIMS: To evaluate the role of pulmonary metastatectomy in hepatocellular carcinoma. METHODOLOGY: Four hepatocellular carcinoma patients underwent pulmonary metastatectomy. Patients were considered candidates for pulmonary metastatectomy when they met the following criteria; 1) intrahepatic hepatocellular carcinoma was under control or anticipated to be under control in the near future; 2) the metastatic lesions appeared to be amenable to complete resection; 3) there was no metastasis at another site. RESULTS: The median duration of follow-up was 4.1 (range: 2.4 to 6.0) years. During this period, 1 patient died of pulmonary recurrence 29 months after metastatectomy. The remaining 3 were alive at the time of writing; one for 43 months after metastatectomy without recurrence; another for 72 months with intrahepatic recurrence; and the third for 54 months with extrahepatic recurrence. CONCLUSIONS: Long-term survival was achieved after pulmonary metastatectomy in highly selected hepatocellular carcinoma patients. However, "highly selected patients" might imply that such patients belong to a special subgroup composed of cases with an intrinsically slow growing tumor biology. Therefore, it is an issue of interest as to whether the long-term survival acquired by these cases results from the pulmonary metastatectomy, or whether it is a reflection of a fate dictated by intrinsic tumor biology.


Subject(s)
Carcinoma, Hepatocellular/secondary , Hepatectomy , Liver Neoplasms/secondary , Lung Neoplasms/secondary , Pneumonectomy , Survivors , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/surgery , Female , Follow-Up Studies , Humans , Korea , Liver/pathology , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Lung/pathology , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Postoperative Complications/mortality , Postoperative Complications/pathology , Prospective Studies , Reoperation
7.
Korean J Gastroenterol ; 42(2): 142-8, 2003 Aug.
Article in Korean | MEDLINE | ID: mdl-14532719

ABSTRACT

BACKGROUND/AIMS: Hepatic stellate cells (HSCs) in the hepatocellular carcinoma are responsible for tumor encapsulation as a host defense mechanism. Recently, it was suggested that HSCs might play an important role in hepatic angiogenesis. Thus, HSCs in the HCC may be involved in tumor angiogenesis and pathogenesis of hepatic carcinogenesis. The purpose of this study was to examine the involvement of activated HSCs in the angiogenesis of hepatoma. METHODS: We investigated the effect of human HSC conditioned medium (CM) on the endothelial cell proliferation with or without stimulation of HepG2 CM, using [3H] thymidine incorporation assay. Additionally, we investigated the effect of HepG2 CM on HSCs proliferation and messenger RNA (mRNA) expression of various pro-angiogenic factors such as interleukin 8 (IL-8), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) in HSCs. RESULTS: HSC CM caused a significant increase in DNA synthesis in human umbilical vein endothelial cells (HUVEC). The endothelial proliferation effect of HSCs was augmented by HepG2 CM. HepG2 CM significantly increased HSCs proliferation and stimulated IL-8 and bFGF mRNA expression in HSCs. CONCLUSIONS: HSCs promote endothelial proliferation through various soluble factors. The soluble factors secreted in HepG2 stimulate HSC proliferation and up-regulate mRNA expression of proangiogenic factors. This result suggests that HSCs may play an important role in the angiogenesis of hepatoma.


Subject(s)
Carcinoma, Hepatocellular/physiopathology , Hepatocytes/physiology , Liver Neoplasms/physiopathology , Cell Division , Cell Line, Tumor , Culture Media, Conditioned , DNA/biosynthesis , Endothelium, Vascular/cytology , Hepatocytes/metabolism , Humans , Interleukin-8/biosynthesis , Vascular Endothelial Growth Factor A/biosynthesis
8.
Histochem Cell Biol ; 118(2): 127-36, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12189516

ABSTRACT

The embryonal origin of hepatic stellate cells (HSCs), the principal cells in hepatic fibrogenesis, is still intriguing. To explore the origin and the differentiation of HSCs, we studied the expression of cytokeratin 18 (CK18) and 19 (CK19), the standard markers of simple epithelial cells, in cultured human HSCs. Hepatic stellate cells were isolated from five normal human livers. In immunofluorescence staining, both clone C-51 anti-CK18 antibody and clone RCK108 anti-CK19 antibody labeled almost all stellate cells in the primary culture. Double immunofluorescence staining for cytokeratin/vimentin and cytokeratin/alpha-smooth muscle actin detected by confocal laser scanning microscopy clearly demonstrated the localization of cytokeratin immunoreactivity in human HSCs. During subsequent cultivation of human HSCs to the tenth passage, immunocytochemical staining and western blot analysis demonstrated gradually decreasing profiles of CK18 and CK19 expression. The progressive reduction of cytokeratin expression was further confirmed in a culture of clone cells originated from a single HSC. In conclusion, both CK18 and CK19 are expressed in cultured human HSCs, and the extent of their expression decreases gradually during prolonged cultivation. Our results suggest that HSCs may be of epithelial origin, and that they undergo the transdifferentiation from epithelial to mesenchymal phenotype during an activation process in vitro.


Subject(s)
Epithelial Cells/cytology , Hepatocytes/cytology , Keratins/metabolism , Mesoderm/cytology , Actins/metabolism , Adult , Cell Culture Techniques , Cell Differentiation , Cell Lineage , Hepatocytes/metabolism , Humans , Immunohistochemistry , Immunophenotyping , Liver Neoplasms/pathology , Vimentin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...